BofA raised the firm’s price target on Boston Scientific (BSX) to $115 from $110 and keeps a Buy rating on the shares. The firm notes the company grew organic revenues 19.5% in Q4 and the initial conservative guide for 2025 came in at 10%-12% organic growth. The Q1 guide was also strong at 14%-16%. This puts Boston Scientific as one of the fastest growing companies in MedTech, argues BofA. This best-in-class growth is starting to look even more durable than most had expected, the firm adds, noting that it sees upside to both the margin/EPS guide.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific reports Q4 adjusted EPS 70c, consensus 66c
- Boston Scientific sees Q1 adjusted EPS 66c-68c, consensus 65c
- Boston Scientific sees FY25 adjusted EPS $2.80-$2.87, consensus $2.81
- Notable companies reporting before tomorrow’s open
- Boston Scientific price target raised to $115 from $110 at TD Cowen